The causal effects of 2,821 protein level ratios on non-small cell lung cancer: a two-sample Mendelian randomization study.

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-02-28 Epub Date: 2025-01-08 DOI:10.21037/tcr-24-1523
Xinyun Zou, Jinlan Shen, Xiaokai Li, Yong Diao, Ling Zhang
{"title":"The causal effects of 2,821 protein level ratios on non-small cell lung cancer: a two-sample Mendelian randomization study.","authors":"Xinyun Zou, Jinlan Shen, Xiaokai Li, Yong Diao, Ling Zhang","doi":"10.21037/tcr-24-1523","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) has a complex etiology, making early diagnosis difficult and leading to high mortality rates, thus necessitating personalized treatment strategies. While protein level ratios have shown potential as biomarkers or therapeutic targets, their causal relationship with NSCLC remains unclear. This study aimed to investigate these causal links using Mendelian randomization (MR), providing insights into potential biomarkers and therapeutic avenues.</p><p><strong>Methods: </strong>We executed an intricate two-sample MR study to explore the stochastic causal links between 2,821 protein level ratios and NSCLC. The genome-wide association study (GWAS) statistics for NSCLC and protein level ratios were sourced from the Finnish Database (version 10) and the UK Biobank, respectively. For the instrumental variables (IVs) related to protein level ratios, we selected IVs with a P value <1.0×10<sup>-5</sup>. Throughout this analysis, we applied five established MR techniques.</p><p><strong>Results: </strong>Our study identified causal relationships between 142 protein level ratios and NSCLC. Notably, the AKR1B1/SUGT1 protein level ratio and the PLPBP/STIP1 protein level ratio demonstrated the most significant negative correlations with NSCLC risk. On the other hand, the ARHGEF12/IRAK4 protein level ratio and the BANK1/LBR protein level ratio exhibited the most significant positive correlations. Furthermore, sensitivity analyses did not reveal any significant heterogeneity or horizontal pleiotropy.</p><p><strong>Conclusions: </strong>Studying specific protein level ratios in patients can reveal the molecular mechanisms and pathological processes of NSCLC, which has certain clinical significance for early diagnosis of NSCLC, understanding drug resistance mechanisms and developing personalized treatment strategies. However, these findings necessitate further validation through extensive clinical research.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"1101-1110"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912077/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1523","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Non-small cell lung cancer (NSCLC) has a complex etiology, making early diagnosis difficult and leading to high mortality rates, thus necessitating personalized treatment strategies. While protein level ratios have shown potential as biomarkers or therapeutic targets, their causal relationship with NSCLC remains unclear. This study aimed to investigate these causal links using Mendelian randomization (MR), providing insights into potential biomarkers and therapeutic avenues.

Methods: We executed an intricate two-sample MR study to explore the stochastic causal links between 2,821 protein level ratios and NSCLC. The genome-wide association study (GWAS) statistics for NSCLC and protein level ratios were sourced from the Finnish Database (version 10) and the UK Biobank, respectively. For the instrumental variables (IVs) related to protein level ratios, we selected IVs with a P value <1.0×10-5. Throughout this analysis, we applied five established MR techniques.

Results: Our study identified causal relationships between 142 protein level ratios and NSCLC. Notably, the AKR1B1/SUGT1 protein level ratio and the PLPBP/STIP1 protein level ratio demonstrated the most significant negative correlations with NSCLC risk. On the other hand, the ARHGEF12/IRAK4 protein level ratio and the BANK1/LBR protein level ratio exhibited the most significant positive correlations. Furthermore, sensitivity analyses did not reveal any significant heterogeneity or horizontal pleiotropy.

Conclusions: Studying specific protein level ratios in patients can reveal the molecular mechanisms and pathological processes of NSCLC, which has certain clinical significance for early diagnosis of NSCLC, understanding drug resistance mechanisms and developing personalized treatment strategies. However, these findings necessitate further validation through extensive clinical research.

2821种蛋白质水平比值对非小细胞肺癌的因果影响:一项双样本孟德尔随机化研究
背景:非小细胞肺癌(NSCLC)病因复杂,早期诊断困难,死亡率高,因此需要个性化的治疗策略。虽然蛋白质水平比值已显示出作为生物标志物或治疗靶点的潜力,但它们与非小细胞肺癌的因果关系尚不清楚。本研究旨在利用孟德尔随机化(MR)研究这些因果关系,为潜在的生物标志物和治疗途径提供见解。方法:我们进行了一项复杂的双样本MR研究,以探索2,821种蛋白质水平比率与非小细胞肺癌之间的随机因果关系。NSCLC全基因组关联研究(GWAS)统计数据和蛋白质水平比值分别来自芬兰数据库(版本10)和英国生物银行。对于与蛋白质水平比值相关的工具变量(IVs),我们选择P值为-5的IVs。在整个分析过程中,我们应用了五种已建立的MR技术。结果:我们的研究确定了142蛋白水平比值与非小细胞肺癌之间的因果关系。值得注意的是,AKR1B1/SUGT1蛋白水平比值和PLPBP/STIP1蛋白水平比值与NSCLC风险呈最显著的负相关。另一方面,ARHGEF12/IRAK4蛋白水平比值和BANK1/LBR蛋白水平比值表现出最显著的正相关。此外,敏感性分析没有显示任何显著的异质性或水平多效性。结论:研究患者特异性蛋白水平比值可揭示非小细胞肺癌的分子机制和病理过程,对早期诊断非小细胞肺癌、了解耐药机制、制定个性化治疗策略具有一定的临床意义。然而,这些发现需要通过广泛的临床研究进一步验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信